Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Uber's stock is trading well below its 52-week high despite healthy free cash flow, improving profitability and concrete growth catalysts (autonomy, European delivery expansion). Market uncertainty has compressed the multiple; we present a staged long trade with defined entry, stop and target that balances upside with near-term volatility risks.
Rosenblatt reduced its 12-month price target on Bentley Systems Inc. to $50 from $58 while retaining a Buy rating. The firm expects the company to post in-line fourth-quarter and fiscal 2025 results on February 26, 2026, and models modest subscription growth. Bentley's recent debt actions and targeted acquisitions, alongside mixed analyst views, un…
Rosenblatt increased its 12-month price target on Adeia Inc. to $30 from $20 and kept a Buy rating following the company’s strong 2025 results and a favorable outcome in its patent litigation with Disney. Adeia reported record quarterly and annual revenue and profits, provided revenue guidance implying about 15% year-over-year growth for 2026 when …
Canaccord Genuity raised its price target on Middleby Corp to $187 from $175 and kept a Buy rating as the company executes a strategic shift toward commercial foodservice. The upgrade follows a December agreement to sell a majority stake in the Residential Kitchen business, a completed closing in February, sizeable share repurchases, and expectatio…
Canaccord Genuity lowered its price target on EverQuote to $28 from $33 while retaining a Buy rating, citing guidance for the first quarter that fell short of expectations even though the company posted revenue and profit beats in the fourth quarter. EverQuote reaffirmed a $1 billion revenue objective over the next two to three years and flagged pl…
Wedbush has initiated coverage of Abivax (ABVX) with an Underperform rating and a $110 price target, signaling roughly 17% downside from recent levels. The firm highlights valuation concerns and substantial downside risk if anticipated deals do not materialize after a 2Q26 data readout. Other brokers maintain bullish stances following positive tria…
Rosenblatt cut its price objective on Autodesk to $330 from $375 while keeping a Buy rating, pointing to recent multiple compression across software peers. The firm expects Autodesk to post a strong fiscal fourth quarter and fiscal 2026 results, with revenue above its $1.91 billion estimate and continued strength in AEC and AutoCAD/LT. The company …
Rosenblatt has reaffirmed a Buy rating on IMAX Corporation and kept a $47.00 price target ahead of the company’s quarterly earnings release. The analyst house bases its valuation on a 13x enterprise value to 2026 EBITDA multiple and highlights the potential of IMAX’s 2026 film lineup, while Benchmark also reports stronger-than-expected Q4 2025 resu…
Travere's FILSPARI (sparsentan) is now the center of the company's revenue story and a near-term regulatory binary that could re-rate the stock. At $30.75 the fundamentals and technicals suggest a tactical long: entry at $30.50, stop at $25.00, and a target at $42.00 tied to prior highs and potential approval/launch upside.
The UK government will subject leading video-on-demand platforms, including Netflix and Amazon Prime Video, to stronger regulation enforced by Ofcom under secondary legislation implementing the Media Act 2024. Services with more than 500,000 UK users will enter a new Tier 1 category and must comply with a VoD standards code modelled on the Broadcas…
Williams Trading has reiterated a Buy rating and a $39.00 price target on Genesco Inc., arguing that the stock’s retreat since January 20, 2026 creates a buying opportunity. The target implies roughly 48% upside from the current share price of $26.38. The firm trimmed near-term revenue and earnings forecasts to reflect store rationalization and a f…
Stifel raised its 12-month price objective on BioMarin Pharmaceutical Inc. to $68 from $61 while retaining a Hold recommendation. The firm highlighted the strategic and financial merits of the Fold Therapeutics transaction even as fourth-quarter 2025 results showed an EPS shortfall and revenue slightly above expectations. Key questions remain aroun…
China's nine-day Lunar New Year holiday produced a strong rebound in domestic travel and consumer spending, with official data showing 596 million domestic trips and 803.5 billion yuan in tourism receipts. Gains were widespread across major cities, scenic areas and lower-tier destinations, while the box office recorded a sharp decline in takings an…
China equities have faced downward pressure so far this year led by internet and auto stocks, driven by earnings revisions in e-commerce and cooling sentiment toward AI hyperscalers. At the same time, market breadth has improved: more than 60% of MSCI China constituents are outperforming the index, with industrials, commodities and pharma/biotech a…
Fulcrum Therapeutics Inc. (NASDAQ: FULC) saw its stock decline about 20% on Tuesday after the company released 12-week results from the 20 mg cohort of its Phase 1b PIONEER trial of pociredir in sickle cell disease. Data from 12 evaluable patients showed a mean absolute fetal hemoglobin gain of 12.2 percentage points and improvements in markers of …
H.C. Wainwright revised its price target for Integra Resources Corp. to $7.00 from $7.25 while keeping a Buy rating, a move the firm says reflects dilution from a recent equity raise priced below the company's net asset value per share. Integra released a three-year operating plan for its Florida Canyon mine that forecasts near-term production of 7…
<p>American Shared Hospital Services (AMS) looks mispriced. Recent headlines around automation and AI replacing clinical services have pushed sentiment lower for capital-intensive, people-driven treatment providers. That worry is misplaced for a company that leases Gamma Knife and other radiosurgery equipment, reported 17% revenue growth in Q1 2025…
H.C. Wainwright reduced its 12-month price target on Armata Pharmaceuticals (ARMP) to $15 from $19 while maintaining a Buy rating. The new target implies roughly 57% upside from the current share price of $9.54. The broker highlighted the Qualified Infectious Disease Product (QIDP) designation for AP-SA02 and the regulatory benefits that designatio…
Futures tied to Canada’s primary equity gauge inched lower on Tuesday as investors weighed a cluster of cross-cutting risks: worries about the impact of powerful artificial intelligence models, unresolved questions over new U.S. global tariffs, and upcoming Canadian bank earnings that may reflect slower loan growth. Moves in materials stocks and co…
Major technology and infrastructure companies have struck a series of multi-billion-dollar contracts to secure artificial intelligence compute, chips and data-center capacity. Agreements span leading chipmakers, cloud providers, data-center operators and AI startups, with some arrangements including equity options, licensing of intellectual propert…
A widely circulated hypothetical report outlining a grim 2028 unemployment outcome tied to rapid AI-driven layoffs has unsettled markets already heavily exposed to the technology. Investors have moved out of software equities and into defensive names and parts of the AI supply chain perceived as durable winners, prompting sharp sectoral divergence …
Needham increased its target price for Ultra Clean Holdings to $70 from $50 while retaining a Buy rating, citing management commentary and upgraded guidance that pushed first-quarter 2026 revenue above expectations. The shares have rallied strongly year-to-date but an independent valuation flagged the stock as overvalued relative to its Fair Value …
H.C. Wainwright raised its price target on Bausch + Lomb (BLCO) to $20 from $17 while reaffirming a Buy rating. The firm pointed to a fourth-quarter revenue beat and company guidance implying 5% to 7% constant currency top-line growth for 2026. Bausch + Lomb posted revenue growth across Vision Care, Surgical and Pharmaceuticals in the fourth quarte…
AES Corporation shares climbed 2% following the announcement of multi-decade energy supply and management agreements with Google for a new data center in Wilbarger County, Texas. The arrangement includes 20-year Power Purchase Agreements, AES ownership and operation of generation assets, and a long-term energy management contract to provide powered…
Director Hunt James Christopher acquired 10,000 shares of Kelly Services Inc (NASDAQ:KELYA) on February 20, 2026, paying an average of $9.5733 per share for a total of $95,733. The transaction increases his direct holdings to 15,976 shares as the company navigates a pending sale of a controlling interest and has implemented a stockholder rights pla…
